Genen­tech dives deep­er in­to the mi­cro­bio­me, ink­ing $534M deal with Mi­cro­bi­ot­i­ca to de­vel­op IBD meds

Roche’s Genen­tech unit is dou­bling down on its study of the mi­cro­bio­me, ink­ing a new deal to­day worth up to $500 mil­lion to de­vel­op meds based on study­ing the gut flo­ra.

The deal is with Cam­bridge, UK-based start­up Mi­cro­bi­ot­i­ca, a spin­out of the Well­come Sanger In­sti­tute. The duo is plan­ning a mul­ti-year part­ner­ship to dis­cov­er, de­vel­op, and com­mer­cial­ize med­i­cines for in­flam­ma­to­ry bow­el dis­ease (IBD).

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.